Follow
Nikolaos Gatselis
Nikolaos Gatselis
Dpt of Medicine, National Expertise Center in Autoimmune Liver Disease, ERN, University of Thessaly
Verified email at uth.gr - Homepage
Title
Cited by
Cited by
Year
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ...
Nature medicine 27 (10), 1752-1760, 2021
4422021
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy
G Papatheodoridis, G Dalekos, V Sypsa, C Yurdaydin, M Buti, J Goulis, ...
Journal of hepatology 64 (4), 800-806, 2016
4362016
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B
GV Papatheodoridis, R Idilman, GN Dalekos, M Buti, H Chi, ...
Hepatology 66 (5), 1444-1453, 2017
3042017
Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics
NK Gatselis, K Zachou, GK Koukoulis, GN Dalekos
World journal of gastroenterology: WJG 21 (1), 60, 2015
2522015
autoimmune hepatitis–current management and challenges
K Zachou, P Muratori, GK Koukoulis, A Granito, N Gatselis, A Fabbri, ...
Alimentary pharmacology & therapeutics 38 (8), 887-913, 2013
2382013
Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of …
K Zachou, N Gatselis, G Papadamou, EI Rigopoulou, GN Dalekos
Journal of hepatology 55 (3), 636-646, 2011
2202011
Adipokines as mediators of endothelial function and atherosclerosis
G Ntaios, NK Gatselis, K Makaritsis, GN Dalekos
Atherosclerosis 227 (2), 216-221, 2013
1912013
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
GV Papatheodoridis, GN Dalekos, C Yurdaydin, M Buti, J Goulis, ...
Journal of hepatology 62 (2), 363-370, 2015
1792015
Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview
GN Dalekos, K Zachou, C Liaskos, N Gatselis
European journal of internal medicine 13 (5), 293-303, 2002
1622002
An open label trial of anakinra to prevent respiratory failure in COVID-19
E Kyriazopoulou, P Panagopoulos, S Metallidis, GN Dalekos, G Poulakou, ...
Elife 10, e66125, 2021
1582021
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
E Kyriazopoulou, T Huet, G Cavalli, A Gori, M Kyprianou, P Pickkers, ...
The Lancet Rheumatology 3 (10), e690-e697, 2021
1402021
Spontaneous spondylodiscitis: presentation, risk factors, diagnosis, management, and outcome
E Kapsalaki, N Gatselis, A Stefos, K Makaritsis, A Vassiou, I Fezoulidis, ...
International Journal of Infectious Diseases 13 (5), 564-569, 2009
1142009
A real‐world study focused on the long‐term efficacy of mycophenolate mofetil as first‐line treatment of autoimmune hepatitis
K Zachou, NK Gatselis, P Arvaniti, S Gabeta, EI Rigopoulou, ...
Alimentary pharmacology & therapeutics 43 (10), 1035-1047, 2016
1122016
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population
GV Papatheodoridis, V Sypsa, G Dalekos, C Yurdaydin, F van Boemmel, ...
Journal of hepatology 68 (6), 1129-1136, 2018
1102018
Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase
CFM Perez, MH Harms, KD Lindor, HR Van Buuren, GM Hirschfield, ...
Official journal of the American College of Gastroenterology| ACG 115 (7 …, 2020
992020
Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?
NK Gatselis, K Zachou, P Papamichalis, GK Koukoulis, S Gabeta, ...
Digestive and liver disease 42 (11), 807-812, 2010
992010
Anti‐cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2‐glycoprotein I cofactor or features of antiphospholipid syndrome
K Zachou, C Liaskos, DK Christodoulou, M Kardasi, G Papadamou, ...
European journal of clinical investigation 33 (2), 161-168, 2003
972003
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B
GV Papatheodoridis, V Sypsa, GN Dalekos, C Yurdaydin, F Van Boemmel, ...
Journal of hepatology 72 (6), 1088-1096, 2020
962020
Clinical and virological heterogeneity of hepatitis delta in different regions world‐wide: the Hepatitis Delta International Network (HDIN)
A Wranke, LM Pinheiro Borzacov, R Parana, C Lobato, S Hamid, ...
Liver International 38 (5), 842-850, 2018
942018
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B
GV Papatheodoridis, GN Dalekos, R Idilman, V Sypsa, F Van Boemmel, ...
Journal of hepatology 73 (5), 1037-1045, 2020
842020
The system can't perform the operation now. Try again later.
Articles 1–20